Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States
This study provides data to support the understanding of the real-world utilization and long-term effectiveness of 1L NIVO + IPI in patients with I/P-risk mRCC. TRAE rates were low relative to clinical trials.
Authors
- Samantha Eiffert (ORCID: https://orcid.org/0000-0002-8612-3807)
- Gurjyot K. Doshi
- Viviana Del Tejo
- Xin Yin (ORCID: https://orcid.org/0000-0002-6935-9383)
- Andrew J. Osterland (ORCID: https://orcid.org/0000-0003-4488-0604)
- Lisa Rosenblatt
- Paul Conkling (ORCID: https://orcid.org/0009-0002-9501-4482)
- Sarah B. Guttenplan
- Ping Shi (ORCID: https://orcid.org/0000-0003-2531-7488)
- Anthony P.C. Yim
Institutions
- Texas Oncology (US)
- Bristol-Myers Squibb (United States) (US)
Publication Details
- Journal
- JCO Clinical Cancer Informatics
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1200/cci.24.00132
- Citations
- 6
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.51